BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16053696)

  • 1. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
    Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
    Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
    Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
    J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
    Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
    Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
    Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
    Markert JM; Cody JJ; Parker JN; Coleman JM; Price KH; Kern ER; Quenelle DC; Lakeman AD; Schoeb TR; Palmer CA; Cartner SC; Gillespie GY; Whitley RJ
    J Virol; 2012 May; 86(9):5304-13. PubMed ID: 22379082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A syngeneic mouse glioma model for study of glioblastoma therapy.
    Weiner NE; Pyles RB; Chalk CL; Balko MG; Miller MA; Dyer CA; Warnick RE; Parysek LM
    J Neuropathol Exp Neurol; 1999 Jan; 58(1):54-60. PubMed ID: 10068314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir.
    Namba H; Tagawa M; Miyagawa T; Iwadate Y; Sakiyama S
    Cancer Gene Ther; 2000 Jun; 7(6):947-53. PubMed ID: 10880027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.
    Andreansky SS; He B; Gillespie GY; Soroceanu L; Markert J; Chou J; Roizman B; Whitley RJ
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11313-8. PubMed ID: 8876132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H; Okano H; Chiocca EA; Saeki Y
    Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
    Parker JN; Meleth S; Hughes KB; Gillespie GY; Whitley RJ; Markert JM
    Cancer Gene Ther; 2005 Apr; 12(4):359-68. PubMed ID: 15678154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSV1716 persistence in primary human glioma cells in vitro.
    Harland J; Papanastassiou V; Brown SM
    Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
    Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
    Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered human herpes simplex virus in the treatment of brain tumours.
    Markert JM; Parker JN; Gillespie GY; Whitley RJ
    Herpes; 2001 Mar; 8(1):17-22. PubMed ID: 11867012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
    Chambers R; Gillespie GY; Soroceanu L; Andreansky S; Chatterjee S; Chou J; Roizman B; Whitley RJ
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1411-5. PubMed ID: 7877992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.